ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 22 of 457 for:    Shingles

Reversible Cerebral Vasoconstriction Syndrome and Varicella Zoster Virus (RCVS&VZV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03509701
Recruitment Status : Not yet recruiting
First Posted : April 26, 2018
Last Update Posted : April 26, 2018
Sponsor:
Collaborators:
Hanyang University
Nowon Eulji Medical Center, Eulji University
Kangbuk Samsung Hospital
Information provided by (Responsible Party):
Sung-Han Kim, Asan Medical Center

Brief Summary:
Among patients with thunderclap headache who were admitted to the four participating hospitals, who has diffuse segmental vasoconstriction on CT angiography or MR angiography will be eligible for the study. Participants who meet the definition of RCVS will be enrolled as the case-patients and others will be enrolled as control-patients. The RCVS group will be defined when two or more neurologists agree by the clinical features and angiographic findings. The result of tests for varicella zoster virus titer will not be opened to neurologists until the end of the study. For case and control patients, tests for varicella zoster virus infection are (1) Pre-existing virological markers (ex. VZV-IgG, IgM, and VZV PCR in CSF or Skin lesion if present) (2) VZV-specific cell mediated immune response (CMI) at the time of admission and one month later (3) VZV in blood measured by quantitative test of viral load with real-time PCR and digital PCR for latent viral load (4) Quantitative test of viral load with real-time PCR in saliva at time of admission and one month later. Reactivation or infection of VZV of patients with RCVS and controls will be compared.

Condition or disease Intervention/treatment
Reversible Cerebral Vasoconstriction Syndrome Varicella-zoster Virus Infection Diagnostic Test: Varicella zoster virus specific T-cell mediated immune response

Detailed Description:

In the previous pilot study, reactivation of VZV was confirmed in 63.6% of the patients as having RCVS by cell mediated immune response (CMI) test and 18.2% by Saliva PCR. None of patients who were simply stressed showed reactivation of VZV. Considering about 20% had false negative results in angiographic findings of RCVS, we set the effect size as 0.63 in group of subjects and 0.12 in group of controls. Using alpha values of 0.05 and beta values of 0.2, we calculated the target number of the study. If the ratio of cases to controls is 1:2, 9 case-patients and 18 control-patients were needed and if the ratio is 1:3, 8 case-patients and 24 control-patients were needed. We expect to enroll 10 case-patients and 20 to 30 control-patients within two years, considering the drop rate of 10~20%.

Baseline clinical information regarding age, sex, smoking history and medical comorbidities including hypertension (treated, systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg at discharge), diabetes (treated, fasting blood glucose ≥126 mg/d), hyperlipidemia (treated, total cholesterol level ≥200 mg/dl or low‐density lipoprotein level ≥140 mg/dl) and coronary artery disease will be collected on admission. Laboratory tests, including complete blood count, blood chemistry, c-reactive protein and erythrocyte sediment rate wil be performed. Images of brain MRI, MR angiography, CT angiography or digital substraction angiography will be gathered if present.

Tests for VZV specific T-cell mediated immune response will be performed by VZV specific IFN-γ ELISPOT. Result will be shown as spot number per 10^6 PBMCs. On the day of blood sample collection, plasma will be isolated and freezed (-80℃). Peripheral mononuclear cells will be separated from the remaining blood samples and keep freezed (-190℃). Melt the frozen peripheral mononuclear cells and inoculate them on a plate (T-Track human IFN-γ, Lophius) with anti-human IFN-γ antibody and inoculate VZV lysate (Microbix) 50 ug/mL on them. After incubating 24 hours, the staining will be performed and the spot will be read in a automated ELISPOT reader (ELR07 reader system, Autoimmune Diagnostika GmbH).

For statistical analysis, patients with thunderclap headache will divided into two groups according to the presence of RCVS. Among them, the rate of infection with varicella zoster virus will be compared and analyzed. Fisher's exact test, Mann-Whitney test, Pearson correlation will be performed. Also, logistic regression analysis will be used, and covariates will be adjusted if needed. Sensitivity and specificity of tests for reactivation of VZV and RCVS will be analyzed too.


Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Association Between Reversible Cerebral Vasoconstriction Syndrome and Herpes Zoster Infection
Estimated Study Start Date : May 1, 2018
Estimated Primary Completion Date : April 30, 2020
Estimated Study Completion Date : April 30, 2020


Group/Cohort Intervention/treatment
Subject (RCVS)
Patients who meet the definition of RCVS. (1) acute and severe headache with or without focal deficits or seizures, (2) uniphasic course without new symptoms more than 1 month after clinical onset, (3) segmental vasoconstriction of cerebral arteries shown by computed tomography angiography (CTA), magnetic resonance angiography (MRA) or transfemoral cerebral angiography (TFCA),(4) normal or near normal cerebrospinal fluid analysis and (5) complete or substantial normalisation of arteries shown by follow-up angiography within 12 weeks.
Diagnostic Test: Varicella zoster virus specific T-cell mediated immune response
Check VZV specific T-cell mediated immune response by IFN-γ ELISPOT assay. Results are shown as spot number per 10^6 PBMCs. Lyse the frozen peripheral blood mononuclear cells and inoculate them on anti-human IFN-γ antibody attached plate (T-Track human IFN-γ, Lophius). Inoculate VZV lysate (Microbix) 50 ug/ml on them. After incubating for 24hours, stain will be performed and read the spot by an automated ELISPOT reader (ELR07 reader system, Autoimmune Diagnostika GmbH)
Other Name: Real time and digital polymerase chain reaction (PCR).

Control
Patients with thunderclap headache and intracranial stenosis, but not diagnosed as RCVS.
Diagnostic Test: Varicella zoster virus specific T-cell mediated immune response
Check VZV specific T-cell mediated immune response by IFN-γ ELISPOT assay. Results are shown as spot number per 10^6 PBMCs. Lyse the frozen peripheral blood mononuclear cells and inoculate them on anti-human IFN-γ antibody attached plate (T-Track human IFN-γ, Lophius). Inoculate VZV lysate (Microbix) 50 ug/ml on them. After incubating for 24hours, stain will be performed and read the spot by an automated ELISPOT reader (ELR07 reader system, Autoimmune Diagnostika GmbH)
Other Name: Real time and digital polymerase chain reaction (PCR).




Primary Outcome Measures :
  1. Infection or reactivation of varicella zoster virus (VZV) [ Time Frame: At the time of enrolled. ]
    Compare prevalence of infection or reactivation of VZV in case-patients and control-patients.


Biospecimen Retention:   Samples With DNA
Blood and saliva


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients who visited Asan medical center, Hanyang University Guri Hospital, Nowon Eulji Medical Center, or Kangbuk Samsung Hospital.
Criteria

Inclusion Criteria:

  • Patients with thunderclap headache and suspicious of intracranial vascular lesion by computed tomographic angiography (CTA) or magnetic resonance angiography (MRA).

Exclusion Criteria:

  • Patients with life threatening medical condition
  • Pregnant or scheduled for pregnancy
  • Unwilling or unable to give informed consent
  • Patients who confirmed vasculitis
  • Patients with genetic disease for vascular disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03509701


Contacts
Contact: Sung-Han Kim, MD.PhD 82-2-3010-3305 kimsunghanmd@hotmail.com
Contact: Hyuk Sung Kwon, MD 82-31-560-2078 kwonhs@hanyang.ac.kr

Sponsors and Collaborators
Asan Medical Center
Hanyang University
Nowon Eulji Medical Center, Eulji University
Kangbuk Samsung Hospital
Investigators
Principal Investigator: Sung-Han Kim, MD.Phd Asan Medical Center

Publications:

Responsible Party: Sung-Han Kim, Prof., Asan Medical Center
ClinicalTrials.gov Identifier: NCT03509701     History of Changes
Other Study ID Numbers: 2018-0385
First Posted: April 26, 2018    Key Record Dates
Last Update Posted: April 26, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Sung-Han Kim, Asan Medical Center:
Reversible cerebral vasoconstriction syndrome
Herpes zoster
Varicella-zoster virus infection

Additional relevant MeSH terms:
Syndrome
Infection
Virus Diseases
Herpes Zoster
Chickenpox
Disease
Pathologic Processes
Herpesviridae Infections
DNA Virus Infections